Partnerships & Mergers

The company receives USD10 million in near-term milestones and stands to earn up to USD 705 million additional milestone payments upon reaching key development and regulatory benchmarks.

The collaboration centers on developing targeted radiopharmaceuticals that leverage Regeneron’s antibody portfolio and VelocImmune mice technology.

C4 Therapeutics will use its proprietary TORPEDO platform to design the degrader payloads, while Roche will oversee antibody selection, conjugation chemistry, preclinical testing, and clinical development

The partnership seeks to unify healthcare data and convert it into actionable insights that healthcare providers, insurance companies, and government agencies can leverage.

A central focus of the partnership is equipping family physicians and other healthcare professionals to better identify and support individuals at risk.

The partnership gives Ajman University students access to three major healthcare facilities: Sheikh Khalifa General Hospital in Umm Al Quwain, Sheikh Khalifa Specialty Hospital in Ras Al Khaimah, and Sheikh Khalifa Medical City in Ajman.

SAT founder and Chief Medical Officer Dr Peter Zilla, alongside co-developers Dr Roman Gottardi and Dr Martin Czerny, confirmed that the results validate the device’s clinical value.

Sha’p Left addresses this directly by positioning its nurse-led surgeries in high-traffic, easily accessible locations such as busy taxi ranks, so that patients can receive care quickly and conveniently.

The partnership directly supports Dubai’s D33 Economic Agenda and aims to establish the emirate as a global leader in HealthTech innovation.

This transaction grants Collegium a second branded ADHD medication to complement its existing Jornay PM offering.